Management of patients who refuse blood transfusion

Chand, Nkiran; Subramanya, H Bala; Rao, G. S. Umamalveswara

doi:10.4103/0019-5049.144680

Cited by 41 publications

(35 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It suggests that those who belong to this faith are less likely to vote than others from different religions. Probably, this is in line with their belief on political neutrality (Chand, Subramanya and Rao, 2014). Consistent with other studies of voting behaviour (Bryant and Wahman, 2017; Bleck and Van de Walle, 2018), we found that those living in urban areas are less likely to vote.…”

Section: Discussionsupporting

confidence: 92%

Malawi at the crossroads: Does the fear of contracting COVID-19 affect the propensity to vote?

Chirwa

Dulani

Sithole

et al. 2020

Preprint

View full text Add to dashboard Cite

The new coronavirus disease (COVID-19) has disrupted ways of life, including political processes. In this paper, we assess the effect of own perceived risk of catching COVID-19 on willingness to vote. The paper draws from a nationally representative survey of adult Malawians (n=1155). Our main method used instrumental variables to account for potential endogeneity. Findings show that 63% of Malawians thought that they are likely to catch COVID-19. Notwithstanding the COVID19 risk, 86% were willing to vote. The regression analysis suggests that an individual’s perceived risk of catching COVID-19 is associated with lower likelihood of voting (β=-0.096; p<0.05). The results suggest that voter turnout in Malawi’s fresh presidential election may have been highly affected by the perceived risk of catching COVID-19. The policy implication is that instituting and enforcing primary preventive measures may help reduce the perceived risk of catching COVID19 and mitigate voter apathy.

show abstract

Section: Discussionsupporting

confidence: 92%

Malawi at the crossroads: Does the fear of contracting COVID-19 affect the propensity to vote?

Chirwa

Dulani

Sithole

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…5 In elective surgeries, the patient can be referred to a center that has dealt with similar cases where preoperative optimization with iron and vitamin B12 supplementation, erythropoietin therapy, use of hypotensive anesthesia, acute hypervolemic hemodilution, and technology like harmonic scalpel and intraoperative cell salvage therapy (cell saver) can be used. 6 However, the scenario in emergency cases is markedly different. All the emphasis is on intraoperative control and recovery of blood.…”

Section: Discussionmentioning

confidence: 99%

“…Pharmacologic agents such as antifibrinolytics and recombinant activated factor VII 6. Red blood cell substitutes (HbOC's) can also be used, but are still in phase-III clinical trials6,7…”

mentioning

confidence: 99%

Faith Cures, Doctor Treats: Management of a Case of Pancreatic Trauma in a Jehovah’s Witness Patient

Dhaliwal

Pawar

Matthew

et al. 2019

IJRSMS

View full text Add to dashboard Cite

The awareness about Jehovah's Witness in India is very poor. One of the fundamentals of their beliefs is prohibition of blood and blood product transfusions. This presents a unique challenge, especially when coupled with massive trauma. We describe a rare case of a patient presenting with massive abdominal trauma who was managed successfully. AbstractKeywords ► Jehovah's Witness ► pancreatic trauma ► distal pancreatectomy ► road traffic accident

show abstract

“…Platelet transfusion has been shown to be effective in the prevention of bleeding, however, it is not always beneficial and it may lead to complications related to infection, allergy, or refractory bleeding. Furthermore, the administration of blood and blood products are prohibited in certain populations due to religious beliefs [13]. Hence, there is a need for agents which may increase endogenous platelet production.…”

Section: Discussionmentioning

confidence: 99%

“…Platelet transfusion can prevent bleeding, but infectious and allergic complications and refractoriness due to alloimmunization may occur [3]. Platelet transfusion is not always beneficial, and certain races religiously disallow administration of blood and blood products [13]. Furthermore, a study conducted by Indian researchers showed that in ~50% of patients with dengue with thrombocytopenia, platelet transfusion did not prevent development of severe bleeding or shorten the time to cessation of bleeding [14].…”

Section: Introductionmentioning

confidence: 99%

Effects of Filgrastim on Thrombocytopenia in Patients with Dengue Fever: A Retrospective Study

Baid¹

2018

VIJ

View full text Add to dashboard Cite

Background: Dengue infection causes hematological disturbances including agranulocytosis, leucopenia, and thrombocytopenia. Platelet transfusion is generally used for hematological corrections, but they are not always useful, and are expensive too. Filgrastim is effective in mobilizing the progenitor cells to stimulate the production of platelets and white blood cells (WBCs) endogenously. Aims: This observational, retrospective, single-center study aimed to evaluate the effects of filgrastim in improving platelet and WBC counts in patients with dengue fever. Methods: Data of patients with dengue fever admitted to Nulife Hospital, Mumbai, who had received filgrastim (Neukine ®), were analyzed. Dengue was diagnosed by the rapid dengue NS1 antigen and dengue IgM/IgG antibody tests. Patients with severe thrombocytopenia (platelet count : <20000/mm 3 with or without bleeding) were given a single subcutaneous dose of filgrastim 300 µg/mL. Patients with dengue hemorrhagic fever and dengue shock syndrome were excluded. Results: Data of 51 patients with dengue fever with thrombocytopenia, or dengue like fever with thrombocytopenia (patients in whom reduction in fever followed by leucocytes and platelets were observed) analyzed. Majority (56.86%) had severe thrombocytopenia (platelet count: <20000/mm 3) at baseline. A significant increase (p<0.001) was observed in the platelet and WBC counts on Days 1 and 2 after filgrastim administration. Doubling of the platelet count was seen in 41 patients within 2 days, and WBC within a day post filgrastim use. Maximum increase (~800%) in platelet count was seen at discharge in patients with baseline platelet count <10000/mm 3. Proportion of patients receiving platelet transfusion was lower after filgrastim use than before its administration (9 vs. 22). Filgrastim use was also associated with improvement in the fever status in majority of patients. None of the patients reported any complications after filgrastim use. Liver, renal and hematological evaluations did not show any adverse effects. The follow-up evaluation post discharge was normalization of hematological parameters (as per the clinician), but did not form part of this study. Conclusion: This is the first study to demonstrate that filgrastim use persistently increases the platelet counts along with white blood cell counts within a day in patients with dengue. Addition of filgrastim to the treatment of dengue may help

show abstract

Management of patients who refuse blood transfusion

Cited by 41 publications

References 35 publications

Malawi at the crossroads: Does the fear of contracting COVID-19 affect the propensity to vote?

Malawi at the crossroads: Does the fear of contracting COVID-19 affect the propensity to vote?

Faith Cures, Doctor Treats: Management of a Case of Pancreatic Trauma in a Jehovah’s Witness Patient

Effects of Filgrastim on Thrombocytopenia in Patients with Dengue Fever: A Retrospective Study

Contact Info

Product

Resources

About